Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mr. Goldbergers has been presenting the RMS medical story to the investment community over the last year. Looks like the story is gaining traction. Its a well deserved feather in his cap.
new 52 week high of $2.25 on strong volume.
Notice inside buying:
Manko (2K @ $2.11: 5.8K @ $2.2) largest shareholder continues to add
Goldberger (500 @ $2.21)
Fletcher (16K @$2.18) initial position
you beat me to the punch here
Toomey will help bring new products to market faster. This includes bringing some digital tech to new products
News: $REPR RMS Medical Products Appoints John Toomey Vice President of Growth and Innovation
Repro Med Systems, Inc. dba RMS Medical Products (OTCQX:REPR) (“RMS Medical”) today announced the appointment of John Toomey to the newly created position of Vice President of Growth and Innovation. Mr. Toomey brings to RMS over 30 years of medical device industry experience ...
Got this from https://marketwirenews.com/news-releases/rms-medical-products-appoints-john-toomey-vice-president-of-growth-and-innovation-8358286.html
repr stock price gains 20% over the last three days. The story is getting out. The question for me is who is telling the story and to whom??
I wonder how the market is receiving the super26 needle set?
Below is a link to the slideshow given by Dan Goldberger
https://d1io3yog0oux5.cloudfront.net/_61f794e344b0bec2d3e3a5bc08ccbe02/rmsmedicalproducts/db/295/2384/pdf/9th+Annual+LD+Micro+Invitational.pdf
There is a lot of meat here and will follow up with some of the things that stood out to me.
https://files.constantcontact.com/8d9857b2301/6fc53748-8411-46e3-a20c-f6a5eec9fd41.pdf
RMS MEDICAL PRODUCTS TO PRESENT AT 9th ANNUAL LD MICRO INVITATIONAL
CHESTER, NY – May 20, 2019 - Repro Med Systems, Inc. dba RMS Medical Products (OTCQX:
REPR) (“RMS Medical”) today announced that Executive Chairman Dan Goldberger is scheduled
to present at the 9th Annual LD Micro Invitational on June 5, 2019. The event is being held at the
Luxe Sunset Hotel in Bel-Air, California.
RMS Medical’s presentation will take place at 10:20 am Pacific Time. A copy of the slides will be
available under the Investor Relations section of RMS Medical’s website:
www.rmsmedicalproducts.com.
Sometimes people will use the demographics and potential market to tell a company's story.
Sometimes people will use the technology to highlight a company's story.
In RMS medical, what I see, is an extremely talented management team and board. A group such is this would not normally be interested in a company of RMS' size unless there was something very special and a potential large payoff down the line due to stock price appreciation. This is the most compelling part of the RMS story which does not get credit.
earnings out
https://ir.rmsmedicalproducts.com/press-releases/detail/34/rms-medical-products-announces-2019-first-quarter-financial
record quarterly revenue of $5million
BUT
Total operating expenses for Q1 2019 rose to $3.2 million from $2.0 million in Q1 2018. The increase of $1.2 million, the majority of which is included in selling, general & administrative expenses, reflected higher legal fees related to ongoing litigation with a competitor, expenses associated with the previously announced executive management changes (which RMS believes have been fully realized as of March 31, 2019), and stock compensation expenses. Total operating expenses for Q1 2019 also included a $0.1 million increase in research and development expenses compared to the prior year period associated with increased headcount and expanded product development activity as we begin to invest in innovation
https://finance.yahoo.com/news/rms-medical-products-schedules-2019-130000495.html
Repro Med Systems, Inc. dba RMS Medical Products (REPR) today announced that it will release its financial results for the first quarter ended March 31, 2019, after the close of the financial markets on Tuesday, April 30, 2019. Management will host a conference call on Wednesday, May 1, 2019 at 9:00 am ET to discuss the results and business activities.
Interested parties may participate in the call by dialing:
(877) 407-9753 (Domestic) or
(201) 493-6739 (International)
Webcast registration: Click Here
Following the live call, a replay will be available for six months on the Company's website, www.rmsmedicalproducts.com, under "Investor Relations."
whyte - here is what I am expecting. 20% plus YOY top line growth. Some sales from last quarter were pushed into this quarter. Hoping to see a penny/share bottom line minimum. I expect to see some increase in R&D expenses and patent related expenses. There will also be some expenses related to the never ending lawsuit with a competitor. Looking for improving gross margins??
Looking to hear what if anything is said about early on relationships with drug companies. Below is a quote from March presentation:
"Established strategic plan to become the preferred drug delivery partner for specific infusion therapies in select markets"
whytestocks, have any predictions to make for Q1 results?
News: $REPR RMS Medical Products Schedules 2019 First Quarter Financial Results and Conference Call
Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced that it will release its financial results for the first quarter ended March 31, 2019, after the close of the financial markets on Tuesday, April 30, 2019. Management will host a conference call on Wednesday, Ma...
Read the whole news https://marketwirenews.com/news-releases/rms-medical-products-schedules-2019-first-quarter-financial-results-and-conference-call-8036154.html
did you notice that it looks like RMS switched PR firms to The Equity Group Inc. This will be a plus
This is a big deal for RMS medical(more sales) and a win for the patients (comfort).
the Super26 Needle Sets utilize a proprietary design to provide 26-gauge comfort with significantly faster flow rates.
“The Super26 Needle Sets support the shift towards faster SCIg infusions while addressing patient comfort concerns via the use of a smaller diameter needle.
News: $REPR RMS Medical Products Receives FDA 510(k) Clearance for HIgh-Flo Super26(TM) Subcutaneous Needle Sets
Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (RMS Medical) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for its HIgh-Flo Super26™ Subcutaneous Needle Sets (“Super 26 Needl...
Find out more https://marketwirenews.com/news-releases/rms-medical-products-receives-fda-510-k-clearance-for-high-flo-super26-tm-subcutaneous-needle-sets-8023518.html
Repro Med Systems, Inc. announced that Dan Goldberger, Executive Chairman, will be presenting at the 29th Annual Oppenheimer Healthcare Conference in New York, NY on Tuesday, March 19th.
3/5/19 - director buys 15k shares at 1.54. Follow the money and make some yourself.
The selling, which started the day after earnings were released, was primarily triggered by disappointing fourth quarter results. The stock price dropped 15% from $1.65 to the $1.40 area it is in now.
The top management team is essentially complete with the addition of Dr Brian Schiller last week. So there will be a minimum of "new hire expenses" in the current quarter.
In the last two days 20k of shares have been bought by insiders. This includes 10K by new board member Rob allen. Insider buying is considered a positive indicator for future stock price movement.
Did the market sell on the news or because of the news? Q4 numbers were disappointing. Management contextualized the numbers by pointing out that some orders were delayed until January and that the quarter included some one time hits. To focus on Q4 numbers is to see the trees and not the forest. The company has laid out a very aggressive growth plan with management incentives based on executing the plan. The management believes that subcutaneous injections are in the early stage of adoptions for new applications(PIDD and CIPD). Existing drugs are being reformulated for subcutaneous injections. Sub Q injections can minimizes lost work time for patient and primary care taker of patients.
I do not think the investor community fully understands the company or the market its in. Additionally I do not think investment community has faith in the management team to execute an ambitious plan. The management team would not put a performance matrix out there unless everyone was onboard and they felt they would succeed.
Additional thoughts and observations on today's earnings release.
R&D and patent expenses both increased significantly.
R&D expenses YOY increased 190K (77K of that in Q4)
Payment for patents YOY increased a 100K
Look for new products to be released. Clinical trials provide a ground floor opportunity to match product to patient needs.
From the press release:
Growth in net sales in 2018 was driven by increased penetration of the PIDD market for SubQ Ig, some early adoption of the CIDP market and clinical trials which are a growing revenue source.
From the press release:
"Strategic Plan adopted with goals of $50 million net revenue, 70%+ Gross Margins and 20%+ annual organic revenue growth through 2022"
The company believes the $50 million dollarrevenue figure can be achieved via organic growth. (Primarily in the PIDD and CIDP markets?) The current revenues are 17.4 million. It would require a 287% increase to hit the 50 million figure. To go from the 17.4 revenue figure would require an annual compounded growth rate of 30%. Check my math.
I believe the company will be bought out or sold before the $50 million goal is achieved!!!
press release about earnings..
https://ir.rmsmedicalproducts.com/press-releases/detail/27/rms-medical-products-announces-record-revenue-and
Below are the headline:
Reported record 2018 revenue of $17.4 million, up 12.4% compared to 2017
Improved 2018 Profitability; improved Gross Margin, record Net Income and Adjusted EBITDA
Significant progress made in strengthening management team and Board in 2018
Strategic Plan adopted with goals of $50 million net revenues, 70%+ Gross Margins and 20%+ annual organic revenue growth through 2022
two things stuck out to me:
One, from the press release, "Growth in net sales in 2018 was driven by increased penetration of the PIDD market for SubQ Ig, some early adoption of the CIDP market and clinical trials which are a growing revenue source."I believe this is how the company will achieve the 50 million revenue from organic growth.This kind of growth will not come without some growing pains.
Two: " For the fourth quarter of 2018, net loss was $355,000 compared to net income of $278,000 during the fourth quarter of 2017 due to the increase in operating expenses"
Total operating expenses for the three months ended December 31, 2018 were $3.1 million compared to $2.1 million during the three months ended December 31, 2017. In the fourth quarter of 2018, RMS went through significant organizational changes and incurred expenditures related to the termination and replacement of C-suite executives and senior management, legal expenses related to activities under the purview of the special committee formed by the Board as previously disclosed, the recruitment of new directors replacing exiting directors and investment banking and legal fees for the recent Common Stock Purchase Agreement the Company executed on December 17, 2018. In aggregate these expenses were $0.6 million for the fourth quarter and $1.0 million for the twelve months ended December 31, 2018. Further driving expenses for the quarter and year were increased costs related to our continued litigation with a competitor, as well compensation expense mostly related to new hires, in aggregate $0.4million for the fourth quarter and $0.4 million for the year.
Long answer short is the fourth quarter took some one time hits, more then I had expected, but they are now behind us and the company can go forward focusing on the business of business.
Earnings for the last quarter of 2018 and financial year 2018 will be released Tuesday after market closes. Expect the last quarter to show 15+% YOY revenue growth. Bottom line growth will include some one time expenses related to the former CEO leaving.
Conference Call Date: Wednesday, February 13, 2019 9:00AM ET
Conference Call Dial-In: 877.269.7756
International Dial-In: 201.689.7817
Conference Call Name: RMS Medical Products (REPR) 2018 Results Call
Webcast Registration: Click Here
https://finance.yahoo.com/news/rms-medical-announces-ceo-strategic-140000458.html
Below is a quote from today's press release clarifying last Friday's S1 filing.
Filing of S-1 Registration Statement in Connection with December 2018 Transaction
On February 1, 2019, the company filed a resale shelf registration statement on Form S-1 related to the previously disclosed private placement transaction between shareholders that concluded on December 20, 2018. The registration statement is limited to the 11,101,697 shares that were transferred in that transaction. The company did not receive any proceeds or sell any shares in connection with that transaction and will not receive any proceeds or sell any shares in connection with the registration statement.
https://finance.yahoo.com/news/rms-medical-announces-ceo-strategic-140000458.html
I do not like posting the content of press releases after posting the link. One Don Pettigrews influence and imprint on the organization continues to expand. There is a plan going forward and there will be pressure to execute. His influence is already impacting sales and expect topline growth when earnings are released next week.
securities-registration-statement-s-1
The shares, which are being made available for sale, are the shares that were bought from Mr. Sealfon and Dr. Baker as part of a private placement in 12/2018. The share price was $1.20
The sellers did not buy the stock to flip it a few months later at a 25 cent gain. I see the security registration is a confirmation that sellers bought the stock believing the company will be sold. This securities registration will allow the share owners to sell and is not a declaration of their intent to sell.
https://ih.advfn.com/stock-market/USOTC/repro-med-systems-inc-qx-REPR/stock-news/79173168/securities-registration-statement-s-1
https://finance.yahoo.com/news/rms-medical-products-announces-private-130000282.html
buyers are nibbling.
expect pre- earning press release any day now.
the trading pattern today looks interesting. One 10k block and a bunch of 2k blocks spread evenly throughout today. This is a difficult stock to buy or sell without moving the gauge because it is so thinly traded.It looks to me like someone is nibbling.
Expect a pre earnings announcement shortly.
mrholty - I am not with the company and do not know the inside story. I have spoken with Mr. Ma several times over the years and always found him pleasant and educational.
RMS is moving from a family type atmosphere under Andy to a professionally results driven corporation. To do this RMS assembled a quality management team and brought in people such as Mr. Pettigrew who has experience in the infusion industry. Below is a link to recent BOD additions. To me people with this pedigree on the RMS board is a big plus
https://www.marketwatch.com/press-release/rms-medical-products-announces-new-board-members-2018-12-06
He was brought in as a consultant in 2015, then a full time employee in 2016 and just got his current position in May 2017. Most of this was done during with the current leadership team.
I have no idea of his skill or qualities but this is not simply cleaning house of prior people who are loyal.
stock repurchase plan. wouild love to see one. would be a big vote of confidence in the company's future.
separation agreement with fred ma
https://ih.advfn.com/stock-market/USOTC/repro-med-systems-inc-qx-REPR/stock-news/78951806/current-report-filing-8-k
Unfortunate but this does not surprise me.
A car will not run smoothly with some of the cylinders misfiring. What I see happening is, as RMS medical upgrades management and board of directors then the bar for excellence and performance, will be raised throughout the organization.
the lack of liquidity in this stock is a huge problem.
Below is the press release and the 8k about the private placement of Sealfon & Company stock
https://finance.yahoo.com/news/rms-medical-products-announces-private-130000282.html
https://ih.advfn.com/stock-market/USOTC/repro-med-systems-inc-qx-REPR/stock-news/78901297/current-report-filing-8-k
This is very positive in that it removes a cloud that has been hanging over the company. The sale broadens institutional ownership. The broader institutional ownership is a vote of confidence in the company. See quote below taken from the press release.
"Purchasers in the transaction included new institutional investors and an existing affiliate of the Company."
rms medical products continues to fill out management team.
https://ih.advfn.com/stock-market/USOTC/repro-med-systems-inc-qx-REPR/stock-news/78847866/current-report-filing-8-k
RMS new board members. The new guys see to have good pedigree. Will be a great resource to help guide the company going forward.
https://ir.rmsmedicalproducts.com/press-releases/detail/22/rms-medical-products-announces-new-board-members
link to the 9th annual Craig-Hallum Alpha Select Conference in New York City on Thursday, November 15th, 2018.
https://www.rmsmedicalproducts.com/wp-content/uploads/2018/11/repr-november-investor-presentation-111318.pdf
I think the presentation was a well was a good overview of the company.
Goldberger is speaking today.
The 9th annual Craig-Hallum Alpha Select Conference in New York City on Thursday, November 15th, 2018.
honestly i think I should sell whenever he speaks.
sprint - not sure how to answer you. Joe Manko and company have been a regular buyer of company stock and now are one of the largest shareholders. They continue to add to their position indicating they believe there is more growth ahead.
For more information about the company visit their homepage,
https://ir.rmsmedicalproducts.com/
Investor relations can be found by going to "who we are">>"investors"
Below is a link to a recent presentation by Dan Goldberger
https://www.rmsmedicalproducts.com/wp-content/uploads/2018/09/repr-september-2018-presentation-rev-9318.pdf
Why I like the company. They have put together a dynamic management team!!
Home infusion. Would you rather take time off from work or be able to self administer the medication at your convenience at home? The answer is obvious. And its cheaper to self administer at home.
If you have more questions then post them and if I can answer them, or clarify something I will.
Hey blue what are we looking at here, just found REPR through market beat insider trades. anything promising soon? noticed Joseph M Jr. Manko (Director) bought up 72,787 shares yesterday.
wearable drug delivery systems.
I am posting this article because much of the logic for moving from hospital administered IV to wearable devices is applicable to the RMS product line. More specifically cost savings and convenience. Also the reformulation and optimization of IV drugs for SC infusions can be accelerated via partnerships between drug makers and device manufactures such as RMS.
https://drug-dev.com/wearable-injectors-a-small-device-that-can-make-a-big-difference-for-iv-infusion/
Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.
https://www.ncbi.nlm.nih.gov/pubmed/25015302
link to cc transcript
https://ir.rmsmedicalproducts.com/all-sec-filings/content/0001161697-18-000509/0001161697-18-000509.pdf
below is the supplemental information concerning horton's management warrants
[SUPPLEMENTAL INFORMATION: On September 13, 2018, Horton Capital Partners Fund, LP notified RMS of its
intention to exercise the warrant, purchased on August 8, 2014 and expiring on August 8, 2019, in full at an
exercise price of $0.45 per share at a closing to take place no earlier than November 12, 2018].
Horton management continues to buy stock in the open market at these levels. This indicates a belief in the company's future and faith that the stock price will continue to appreciate.
the questions of the horton's warrants is addressed via the conference call transcript see below:
On October 24, 2018, Repro Med Systems, Inc. dba RMS Medical Products (the “Company”) held an earnings conference call for the quarter ended September 30, 2018. A copy of the conference call transcript is attached hereto as Exhibit 99.1. The transcript contains certain supplemental information identified by “[ ]” related to management’s responses to investor questions.
Horton wants to grow the company. That is why they worked to help put in the current board members and management team. It is not Horton's intent to flip the stock. Exercising the warrants strengthens their position in the event of a proxy fight by the former ceo and sealfon. Just my opinion.
mrholty - My take away from the CC was positive. The company is growing and it looks like the growth is accelerating. I was especially impressed with Don Pettigrew. He has been there less then two months. He will transform the sales and marketing of the rms product line.
Followers
|
68
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2463
|
Created
|
09/18/00
|
Type
|
Free
|
Moderators |
You may have heard of Repro Med Systems, Inc. That’s us! Today, we are operating as RMS Medical Products, a leading developer and manufacturer of medical devices and supplies. The company was incorporated in March, 1980 and is now publicly traded . Our stock symbol is REPR.
Worldwide, RMS Medical Products drives healthcare inspiration – in the minds of our patients, our employees, our customers and our shareholders – to give everyone greater freedom for living. We design and manufacture safe, affordable medical devices to make quality healthcare a reality for everyone.
We focus on home and specialty infusion solutions, emphasizing responsive problem-solving for our customers, and careful consideration for the patient experience. Our primary products are the FREEDOM60® and FreedomEdge® DynEQ Infusion Systems, RMS Precision Flow Rate Tubing™, HIgH-Flo Subcutaneous Safety Needle Sets™ and RES-Q-VAC® Hand Held Medical Suction.
We are passionate about helping people with our reliable medical devices made at our HQ in Chester, NY (USA). Our products, as well as product support, are offered worldwide by RMS and through a global network of distributors and service providers.
RMS is excited to expand into new markets with innovative, more technical products. We look forward to productive partnerships with people and companies who share our vision and can help us effectively deliver our value promise to stakeholders in our industry.
Web Site
http://www.repro-med.com
Main Products
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |